Intercure Ltd (INCR)

$0.93 -0.01 (-0.88%)
Market Cap 42.06M
Revenue (ttm) 66.28M
Net Income (ttm) -18.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -27.64%
Debt to Equity Ratio 0.22
Volume 26,328
Avg Vol 92,568
Day's Range N/A - N/A
Shares Out 45.57M
Stochastic %K 71%
Beta 1.21
Analysts Strong Buy
Price Target $7.00

Company Profile

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company has a strategic alliance with Cannasoul R&D Ltd. for the research, development, and commercialization of evidence-based cannabis t...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 7 746 05012
Fax: 972 9 768 0244
Address:
85 Medinat ha-Yehudim Street, Herzliya, Israel
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 3 at 10:45 AM
$INCR RSI: 38.54, MACD: -0.0603 Vol: 0.03, MA20: 0.95, MA50: 1.14 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Renato17
Renato17 Feb. 2 at 11:26 PM
$MSOS LIVE ON Z&A: Israel Market Outlook, Import & Export Potential @INTER_CURE $INCR $INCR.U @cronosgroup @mgorenst $CRON Pablo Zuanic @420Odysseus #Cannabis #cannabisindustry
0 · Reply
JesusWhale
JesusWhale Jan. 8 at 1:12 PM
$INCR down 35% on no fundamental changes or news. Company needs to release some sort of update or release 2H of 2025 earnings
0 · Reply
D1gitalN0mad
D1gitalN0mad Jan. 2 at 4:56 PM
$INCR what in the world is going on here? $1 seems way too cheap
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 26 at 4:23 PM
$INCR Share Price: $1.13 Contract Selected: Jul 17, 2026 $2.5 Calls Buy Zone: $0.09 – $0.11 Target Zone: $0.16 – $0.20 Potential Upside: 68% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JesusWhale
JesusWhale Dec. 24 at 3:34 PM
$INCR some MM is intentionally pushing this down and holding it back. Inflows have been nothing but positive, with numerous big guys over the last 5 trading sessions. I am loading the boat these prices!
0 · Reply
diamondtouch
diamondtouch Dec. 16 at 5:12 PM
$INCR surprising this company continues to struggle despite its connection to Israel. At this time it appears management is incompetent, but time will tell. I invested in 2022 when revenue and net income was rising. Revenue was up the last two quarters but far from the $388M in 2022..
2 · Reply
WallStWireAds
WallStWireAds Dec. 12 at 8:21 PM
$INCR $TLRY $CGC $SNDL https://www.benzinga.com/content/49366233/intercure-may-be-uniquely-positioned-as-trumps-cannabis-rescheduling-returns-to-headlines-nasdaq-inc
0 · Reply
WallStWireAds
WallStWireAds Dec. 12 at 10:55 AM
$INCR https://thefinanceherald.com/trumps-rescheduling-is-back-in-play-and-this-microcap-may-be-uniquely-positioned-for-a-breakout/
0 · Reply
WallStWireAds
WallStWireAds Nov. 10 at 12:36 AM
$INCR https://thefinanceherald.com/trumps-cannabis-rescheduling-push-could-redefine-the-industry-and-intercure-is-already-expanding-its-scientific-edge/
0 · Reply
Latest News on INCR
InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation

Nov 3, 2025, 8:30 AM EST - 3 months ago

InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation

InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow

Oct 8, 2025, 9:40 AM EDT - 4 months ago

InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow

InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands

Sep 19, 2025, 8:48 AM EDT - 4 months ago

InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands

InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025

May 1, 2025, 4:00 PM EDT - 9 months ago

InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025

InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak

Feb 12, 2025, 6:35 PM EST - 1 year ago

InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak

InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

Dec 20, 2024, 8:32 AM EST - 1 year ago

InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility

Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company

Sep 14, 2024, 2:32 PM EDT - 1 year ago

Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

Aug 29, 2024, 6:03 PM EDT - 1 year ago

InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million

InterCure Announces Expansion of its Strategic partnership with Cookies to Germany

Aug 28, 2024, 8:54 AM EDT - 1 year ago

InterCure Announces Expansion of its Strategic partnership with Cookies to Germany

InterCure: A Cannabis Industry Leader Still Flying Under The Radar

Jun 30, 2024, 3:42 AM EDT - 1 year ago

InterCure: A Cannabis Industry Leader Still Flying Under The Radar

InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference

May 22, 2024, 6:45 AM EDT - 1 year ago

InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference

InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million

May 1, 2024, 8:27 AM EDT - 1 year ago

InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million

InterCure: Bargain Israel Cannabis Play

Apr 22, 2024, 3:41 PM EDT - 1 year ago

InterCure: Bargain Israel Cannabis Play

InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million

Apr 1, 2024, 9:09 AM EDT - 2 years ago

InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million

InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint

Mar 22, 2024, 11:58 AM EDT - 2 years ago

InterCure Congratulates Germany on Cannabis Reform, Expanding its Global Footprint

PESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis Landscape

Feb 23, 2024, 12:12 PM EST - 2 years ago

PESG Industry Updates: Germany's Cannabis Act and Its Impact on the Medical Cannabis Landscape

InterCure Provides an Update Regarding Nir Oz Facility

Feb 13, 2024, 4:46 PM EST - 2 years ago

InterCure Provides an Update Regarding Nir Oz Facility

InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain

Jan 31, 2024, 9:27 AM EST - 2 years ago

InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain

InterCure Wins Cannolam Arbitration Proceeding

Oct 31, 2023, 4:39 PM EDT - 2 years ago

InterCure Wins Cannolam Arbitration Proceeding

InterCure Provides an Update Regarding the Security Situation in Israel

Oct 17, 2023, 5:04 PM EDT - 2 years ago

InterCure Provides an Update Regarding the Security Situation in Israel

InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY

Aug 31, 2023, 7:45 PM EDT - 2 years ago

InterCure Announces Record Revenues First Half of 2023 with over 14% growth YOY

InterCure: Leader In Israel's Growing Medical Cannabis Market

Aug 2, 2023, 7:22 PM EDT - 2 years ago

InterCure: Leader In Israel's Growing Medical Cannabis Market

InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE

Jul 10, 2023, 5:00 PM EDT - 2 years ago

InterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASE

InterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

Jun 9, 2023, 5:18 PM EDT - 2 years ago

InterCure Provides an Update About The Lawsuit it Filed Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

InterCure to Participate in the Cowen 3rd Annual European Cannabis Conference

May 15, 2023, 5:59 PM EDT - 2 years ago

InterCure to Participate in the Cowen 3rd Annual European Cannabis Conference

InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY

May 15, 2023, 5:45 PM EDT - 2 years ago

InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOY

InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary

Apr 25, 2023, 7:19 PM EDT - 3 years ago

InterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its Subsidiary

InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries

Apr 20, 2023, 8:30 AM EDT - 3 years ago

InterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU Countries

InterCure: How Bright Is The Company's Future In 2023

Apr 6, 2023, 10:24 AM EDT - 3 years ago

InterCure: How Bright Is The Company's Future In 2023

InterCure Ltd. (INCR) Q4 2022 Earnings Call Transcript

Apr 4, 2023, 6:56 PM EDT - 3 years ago

InterCure Ltd. (INCR) Q4 2022 Earnings Call Transcript

InterCure Reschedules 2022 Full Year Results Conference Call

Apr 3, 2023, 3:27 PM EDT - 3 years ago

InterCure Reschedules 2022 Full Year Results Conference Call

InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results

Mar 31, 2023, 8:00 PM EDT - 3 years ago

InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results

InterCure Files Lawsuit Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

Feb 14, 2023, 8:30 AM EST - 3 years ago

InterCure Files Lawsuit Against Cann Pharmaceuticals to Recover Funds Following Failed Merger

InterCure Announces the Termination of its Acquisition Agreement with Cann Pharmaceutical (dba Better)

Feb 1, 2023, 8:30 AM EST - 3 years ago

InterCure Announces the Termination of its Acquisition Agreement with Cann Pharmaceutical (dba Better)

InterCure: Why The Company Is Grossly Undervalued By Wall Street

Jan 20, 2023, 12:22 PM EST - 3 years ago

InterCure: Why The Company Is Grossly Undervalued By Wall Street

Cannabis Is A Long-Term Play (Podcast Transcript)

Jan 9, 2023, 6:30 AM EST - 3 years ago

Cannabis Is A Long-Term Play (Podcast Transcript)

Cannabis REITs: Smoked Out

Dec 29, 2022, 11:15 AM EST - 3 years ago

Cannabis REITs: Smoked Out

ACB AFCG BYND CARA CGC CNBS CRON

InterCure Announces Exclusive International Partnership Agreement with Award Winning Cannabis Brand "Binske"

Dec 19, 2022, 8:30 AM EST - 3 years ago

InterCure Announces Exclusive International Partnership Agreement with Award Winning Cannabis Brand "Binske"

InterCure to Participate in Cowen 5th Annual Cannabis Conference

Dec 8, 2022, 9:30 AM EST - 3 years ago

InterCure to Participate in Cowen 5th Annual Cannabis Conference

Update regarding Better Transaction

Nov 23, 2022, 4:30 PM EST - 3 years ago

Update regarding Better Transaction

Organigram and Intercure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies

Nov 17, 2022, 8:17 AM EST - 3 years ago

Organigram and Intercure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies

Organigram and InterCure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies

Nov 17, 2022, 8:00 AM EST - 3 years ago

Organigram and InterCure (dba : Canndoc) Sign New International Strategic Agreement Representing Largest Such Deal to Date for Both Companies

OGI

CORRECTION and MULTIMEDIA UPDATE -- InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth

Nov 15, 2022, 11:18 AM EST - 3 years ago

CORRECTION and MULTIMEDIA UPDATE -- InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth

InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth

Nov 15, 2022, 9:03 AM EST - 3 years ago

InterCure Announces Record Breaking Third Quarter Financial Results with 63% growth YOY and 6% QoQ growth

InterCure Announces Record Preliminary Third Quarter Revenue of Over CAD$39 million – 63% Growth YoY

Nov 11, 2022, 8:32 AM EST - 3 years ago

InterCure Announces Record Preliminary Third Quarter Revenue of Over CAD$39 million – 63% Growth YoY

Buy InterCure To Ride The Coming Wave Of Global Cannabis Growth

Nov 8, 2022, 11:42 PM EST - 3 years ago

Buy InterCure To Ride The Coming Wave Of Global Cannabis Growth

InterCure: Highlighting A Profitable Israeli Cannabis Operator

Oct 25, 2022, 12:11 PM EDT - 3 years ago

InterCure: Highlighting A Profitable Israeli Cannabis Operator

Intercure Ltd. Announces Voting Results from its Annual and Special Meeting of Shareholders

Sep 16, 2022, 4:30 PM EDT - 3 years ago

Intercure Ltd. Announces Voting Results from its Annual and Special Meeting of Shareholders

InterCure: A Leader In Global Cannabis

Sep 6, 2022, 5:25 PM EDT - 3 years ago

InterCure: A Leader In Global Cannabis

InterCure Ltd (INCR) CEO Alexander Rabinovitch on Q2 2022 Results - Earnings Call Transcript

Aug 16, 2022, 2:11 PM EDT - 3 years ago

InterCure Ltd (INCR) CEO Alexander Rabinovitch on Q2 2022 Results - Earnings Call Transcript

OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 3 at 10:45 AM
$INCR RSI: 38.54, MACD: -0.0603 Vol: 0.03, MA20: 0.95, MA50: 1.14 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Renato17
Renato17 Feb. 2 at 11:26 PM
$MSOS LIVE ON Z&A: Israel Market Outlook, Import & Export Potential @INTER_CURE $INCR $INCR.U @cronosgroup @mgorenst $CRON Pablo Zuanic @420Odysseus #Cannabis #cannabisindustry
0 · Reply
JesusWhale
JesusWhale Jan. 8 at 1:12 PM
$INCR down 35% on no fundamental changes or news. Company needs to release some sort of update or release 2H of 2025 earnings
0 · Reply
D1gitalN0mad
D1gitalN0mad Jan. 2 at 4:56 PM
$INCR what in the world is going on here? $1 seems way too cheap
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 26 at 4:23 PM
$INCR Share Price: $1.13 Contract Selected: Jul 17, 2026 $2.5 Calls Buy Zone: $0.09 – $0.11 Target Zone: $0.16 – $0.20 Potential Upside: 68% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
JesusWhale
JesusWhale Dec. 24 at 3:34 PM
$INCR some MM is intentionally pushing this down and holding it back. Inflows have been nothing but positive, with numerous big guys over the last 5 trading sessions. I am loading the boat these prices!
0 · Reply
diamondtouch
diamondtouch Dec. 16 at 5:12 PM
$INCR surprising this company continues to struggle despite its connection to Israel. At this time it appears management is incompetent, but time will tell. I invested in 2022 when revenue and net income was rising. Revenue was up the last two quarters but far from the $388M in 2022..
2 · Reply
WallStWireAds
WallStWireAds Dec. 12 at 8:21 PM
$INCR $TLRY $CGC $SNDL https://www.benzinga.com/content/49366233/intercure-may-be-uniquely-positioned-as-trumps-cannabis-rescheduling-returns-to-headlines-nasdaq-inc
0 · Reply
WallStWireAds
WallStWireAds Dec. 12 at 10:55 AM
$INCR https://thefinanceherald.com/trumps-rescheduling-is-back-in-play-and-this-microcap-may-be-uniquely-positioned-for-a-breakout/
0 · Reply
WallStWireAds
WallStWireAds Nov. 10 at 12:36 AM
$INCR https://thefinanceherald.com/trumps-cannabis-rescheduling-push-could-redefine-the-industry-and-intercure-is-already-expanding-its-scientific-edge/
0 · Reply
Hila11
Hila11 Oct. 9 at 1:28 PM
$CGEN $INCR 🔥🚀🔥🚀 https://www.biospace.com/press-releases/intercure-reports-first-half-2025-results-with-nis-130-million-in-revenue-and-positive-operating-cash-flow
0 · Reply
Hila11
Hila11 Oct. 9 at 1:27 PM
$BIAF $INCR 🔥🚀🔥 https://www.biospace.com/press-releases/intercure-reports-first-half-2025-results-with-nis-130-million-in-revenue-and-positive-operating-cash-flow
0 · Reply
Hila11
Hila11 Oct. 9 at 1:27 PM
$XTLB $INCR 🔥🚀🔥🚀 https://www.biospace.com/press-releases/intercure-reports-first-half-2025-results-with-nis-130-million-in-revenue-and-positive-operating-cash-flow
0 · Reply
Hila11
Hila11 Oct. 9 at 1:25 PM
$NVMI $INCR 🔥🚀🔥🚀 https://www.biospace.com/press-releases/intercure-reports-first-half-2025-results-with-nis-130-million-in-revenue-and-positive-operating-cash-flow
0 · Reply
Hila11
Hila11 Oct. 9 at 1:25 PM
$GILT $INCR 🔥🚀🔥🔥 https://www.biospace.com/press-releases/intercure-reports-first-half-2025-results-with-nis-130-million-in-revenue-and-positive-operating-cash-flow
0 · Reply
Hila11
Hila11 Oct. 9 at 1:24 PM
$ARBE $INCR 🔥🚀🔥 https://www.biospace.com/press-releases/intercure-reports-first-half-2025-results-with-nis-130-million-in-revenue-and-positive-operating-cash-flow
0 · Reply
Hila11
Hila11 Oct. 9 at 1:23 PM
$KDK $INCR 🔥🚀🔥 https://www.biospace.com/press-releases/intercure-reports-first-half-2025-results-with-nis-130-million-in-revenue-and-positive-operating-cash-flow
0 · Reply
Hila11
Hila11 Oct. 9 at 1:18 PM
$INCR 🚀🔥🔥 https://www.biospace.com/press-releases/intercure-reports-first-half-2025-results-with-nis-130-million-in-revenue-and-positive-operating-cash-flow
0 · Reply
Avi1970
Avi1970 Oct. 8 at 5:45 PM
$INCR The reports are good, the stock should rise, not fall.
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 4:40 AM
$INCR Excellent article that nails exactly where INCR stands right now. So if you want to update your INCR knowledge or get acquainted with INCR, this is a must read. https://beyondspx.com/quote/INCR/analysis/intercure-s-global-cannabis-ambition-leveraging-gmp-and-tech-for-market-dominance-nasdaq-incr
0 · Reply
Avi1970
Avi1970 Sep. 30 at 5:16 PM
$INCR Who are we waiting for?
0 · Reply
WallStWireAds
WallStWireAds Sep. 30 at 12:53 PM
$INCR $TLRY
0 · Reply